Roger Adsett Sells 2,444 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM - Get Free Report) COO Roger Adsett sold 2,444 shares of Insmed stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $65.95, for a total transaction of $161,181.80. Following the transaction, the chief operating officer now owns 147,666 shares in the company, valued at approximately $9,738,572.70. This trade represents a 1.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Roger Adsett also recently made the following trade(s):

• On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The shares were sold at an average price of $63.68, for a total value of $312,159.36.

Insmed Trading Down 0.7 %

Shares of INSM stock traded down $0.47 during trading hours on Friday, reaching $65.25. 3,087,759 shares of the stock were exchanged, compared to its average volume of 1,881,810. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $80.53. The firm has a market capitalization of $11.67 billion, a price-to-earnings ratio of -11.76 and a beta of 1.12. The company's 50-day moving average price is $71.29 and its 200-day moving average price is $72.44.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analysts' expectations of $93.36 million. During the same quarter last year, the company posted ($1.10) earnings per share. The business's revenue was up 18.1% on a year-over-year basis. As a group, equities analysts anticipate that Insmed Incorporated will post -5.44 earnings per share for the current year.

Institutional Trading of Insmed

Large investors have recently made changes to their positions in the stock. V Square Quantitative Management LLC bought a new stake in Insmed during the 3rd quarter valued at about $30,000. GAMMA Investing LLC grew its stake in Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 224 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in Insmed by 522.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company's stock worth $55,000 after purchasing an additional 627 shares during the period. Blue Trust Inc. raised its position in Insmed by 2,348.8% during the 3rd quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company's stock valued at $131,000 after purchasing an additional 1,879 shares in the last quarter. Finally, JCIC Asset Management Inc. purchased a new stake in shares of Insmed in the 3rd quarter worth $133,000.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on INSM. HC Wainwright reiterated a "buy" rating and set a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. JPMorgan Chase & Co. lifted their price target on shares of Insmed from $74.00 to $83.00 and gave the company an "overweight" rating in a report on Friday, November 22nd. Bank of America increased their price objective on shares of Insmed from $84.00 to $86.00 and gave the company a "buy" rating in a report on Wednesday, October 9th. Finally, Truist Financial reiterated a "buy" rating and issued a $105.00 target price (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Insmed has a consensus rating of "Moderate Buy" and an average target price of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.